Hims and Hers Health (NYSE: HIMS) is working to convert GLP-1 demand, subscriber increases, and global expansion into a significantly larger healthcare platform. Shares have fallen notably, margins are under strain, and valuation still seems demanding, yet long-term potential could grow more attractive if Hims can effectively promote additional higher-margin offerings.

Stock prices referenced were the market prices of May 28, 2026. The video was published on June 4, 2026.

Will AI produce the world's first trillionaire? Our team has just released a report on the one lesser-known company, called an "Indispensable Monopoly," supplying essential technology that both Nvidia and Intel require. Continue reading »

Should investors purchase shares in Hims and Hers Health now?

Before buying stock in Hims and Hers Health, consider the following:

The Motley Fool Stock Advisor analyst team recently identified what they view as the 10 best stocks for investors to buy now… and Hims and Hers Health was not included. The 10 stocks selected could deliver substantial returns in the years ahead.

For instance, when Netflix appeared on this list on December 17, 2004... an investment of $1,000 at that time would now equal $439,847!* Similarly, when Nvidia was featured on April 15, 2005... $1,000 invested then would now be worth $1,342,065!*

It is worth noting that Stock Advisor’s overall average return reaches 968% — significantly outperforming the 211% return of the S and P 500. Do not miss the latest top 10 list, available through Stock Advisor, and join an investing community created by individual investors for individual investors.

View the 10 stocks »

*Stock Advisor returns as of June 5, 2026.

Rick Orford holds no position in any of the stocks mentioned. The Motley Fool maintains positions in and recommends Hims and Hers Health. The Motley Fool follows a disclosure policy. Rick Orford is affiliated with The Motley Fool and may receive compensation for promoting its services. If you subscribe through their link, they will earn revenue that supports their channel. Their opinions are their own and remain independent of The Motley Fool.

The views and opinions expressed here are those of the author and do not necessarily reflect the positions of Nasdaq, Inc.